Montelukast is not effective in controlling allergic symptoms outside the airways: A randomised double-blind placebo-controlled crossover study

International Archives of Allergy and Immunology

Volumn 149, Issue 2, 2009, Pages 150-153

  Lehtimäki, Lauri ^a,b   Petäys, Tuula ^a   Haahtela, Tari ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Allergic conjunctivitis; Allergic rhinitis; Asthma; Atopic dermatitis; Atopic syndrome; Montelukast

Indexed keywords

ACRIVASTINE; DIPHENHYDRAMINE; MONTELUKAST; NITRIC OXIDE; PLACEBO; SALBUTAMOL;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; ATOPY; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ECZEMA; FEMALE; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT; MALE; NOSE CONGESTION; OCULAR PRURITUS; ORAL PRURITUS; OUTCOME ASSESSMENT; POLLEN ALLERGY; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SKIN REDNESS; SKIN SENSITIZATION; SLEEP DISORDER; SNEEZING; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT; URTICARIA;

ACETATES; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERSENSITIVITY; LEUKOTRIENE ANTAGONISTS; MALE; POLLEN; QUINOLINES; TREATMENT FAILURE; YOUNG ADULT;

EID: 58149144293     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189198     Document Type: Article

References (9)

1. Capra V, Ambrosio M, Riccioni G, Rovati GE: Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006; 13:3213-3226.
2. Pei AY, Chan HH, Leung TF: Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pedi-atr Allerg y Immunol 2001; 12: 154-158.
3. Ehlayel MS, Bener A, Sabbah A: Montelukast treatment in children with moderately severe atopic dermatitis. Allerg Immunol (Paris) 2007; 39:232-236.
4. Veien NK, Busch-Sorensen M, Stausbol-Gron B: Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2005; 53: 147-149.
5. Friedmann PS, Palmer R, Tan E, Ogboli M, Barclay G, Hotchkiss K, Berth-Jones J: A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007; 37:1536-1540.
6. Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, Martinelli N, Rini GB: Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and deslo-ratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Aller-g y Clin Immunol 2004; 114:619-625.
7. Godse KV: Oral montelukast monotherapy is ineffective in chronic idiopathic urticaria: a comparison with oral cetirizine. Indian J Dermatol Venereol Leprol 2006; 72: 312-314.
8. Di Lorenzo G, Pacor ML, Mansueto P, Esposito-Pellitteri M, Ditta V, Lo Bianco C, Leto-Barone MS, Di Fede G, Rini GB: Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol 2006; 31:327-334.
9. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM, British Society for Allergy and Clinical Immunology: BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Al-lergy 2007; 37: 631-650.